Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00098774 · ClinicalTrials.gov registry record · Phase 2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
47
Enrollment target
20
Study locations

NCT00098774 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 47 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00098774, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
47 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well rituximab given with combination chemotherapy works in treating patients with newly diagnosed primary CNS lymphoma.

Conditions Studied

Lymphoma

Interventions

  • BIOLOGICAL rituximab
  • DRUG etoposide
  • DRUG leucovorin calcium
  • BIOLOGICAL filgrastim
  • DRUG cytarabine

Study Locations (20)

Missouri

  • Truman Medical Center - Hospital Hill - Kansas City
  • Saint Luke's Cancer Institute at Saint Luke's Hospital - Kansas City
  • St. Joseph Medical Center - Kansas City
  • North Kansas City Hospital - Kansas City
  • Parvin Radiation Oncology - Kansas City
  • CCOP - Kansas City - Kansas City
  • Research Medical Center - Kansas City
  • Saint Luke's East - Lee's Summit - Lee's Summit
  • Liberty Hospital - Liberty

Kansas

  • Menorah Medical Center - Overland Park
  • Saint Luke's Hospital - South - Overland Park
  • Shawnee Mission Medical Center - Shawnee Mission

Delaware

  • Tunnell Cancer Center at Beebe Medical Center - Lewes
  • CCOP - Christiana Care Health Services - Newark

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Illinois

  • University of Chicago Cancer Research Center - Chicago

Indiana

  • Fort Wayne Medical Oncology and Hematology - Fort Wayne

Iowa

  • Hematology Oncology Associates of the Quad Cities - Bettendorf

Maryland

  • Union Hospital Cancer Program at Union Hospital - Elkton MD

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2004-10
Est. Completion 2014-09
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00098774

The ClinicalTrials.gov registry entry for NCT00098774 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which rituximab is the first listed.

NCT00098774 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Missouri, Kansas, Delaware.

Frequently Asked Questions

What is clinical trial NCT00098774 about?

NCT00098774 is a clinical study titled "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spre...

What is the current status of trial NCT00098774?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2004-10. Estimated completion is 2014-09.

What conditions does trial NCT00098774 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00098774?

The interventions under investigation include: rituximab (BIOLOGICAL), etoposide (DRUG), leucovorin calcium (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).

Who is sponsoring clinical trial NCT00098774?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00098774 being conducted?

This trial has 20 study locations across California, Delaware, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.